Results 21 to 30 of about 8,132 (145)

Signal regulatory protein alpha initiates cachexia through muscle to adipose tissue crosstalk

Journal of Cachexia, Sarcopenia and Muscle, 2019
Background Muscle wasting from chronic kidney disease (CKD) or from defective insulin signalling results in morbidity and, ultimately, mortality. We have identified an endogenous mediator of insulin resistance, signal regulatory protein alpha (SIRPα ...
Jiao Wu, Jiangling Dong, Daniela Verzola, Keith Hruska, Giacomo Garibotto, Zhaoyong Hu, William E. Mitch, Sandhya S. Thomas   +7 more
doaj   +1 more source

SIRPα on Mouse B1 Cells Restricts Lymphoid Tissue Migration and Natural Antibody Production

Frontiers in Immunology, 2020
The inhibitory immunoreceptor SIRPα is expressed on myeloid and neuronal cells and interacts with the broadly expressed CD47. CD47-SIRPα interactions form an innate immune checkpoint and its targeting has shown promising results in cancer patients. Here,
Katka Franke, Saravanan Y. Pillai, Mark Hoogenboezem, Marion J. J. Gijbels, Marion J. J. Gijbels, Hanke L. Matlung, Judy Geissler, Hugo Olsman, Chantal Pottgens, Patrick J. van Gorp, Maria Ozsvar-Kozma, Yasuyuki Saito, Takashi Matozaki, Taco W. Kuijpers, Taco W. Kuijpers, Rudi W. Hendriks, Georg Kraal, Christoph J. Binder, Menno P. J. de Winther, Menno P. J. de Winther, Timo K. van den Berg, Timo K. van den Berg   +21 more
doaj   +1 more source

Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint

Journal for ImmunoTherapy of Cancer, 2019
Background Accumulating preclinical data indicate that targeting the SIRPα/CD47 axis alone or in combination with existing targeted therapies or immune checkpoint inhibitors enhances tumor rejection.
Erik Voets, Marc Paradé, David Lutje Hulsik, Sanne Spijkers, Wout Janssen, Joost Rens, Inge Reinieren-Beeren, Gilbert van den Tillaart, Sander van Duijnhoven, Lilian Driessen, Maurice Habraken, Peter van Zandvoort, Joost Kreijtz, Paul Vink, Andrea van Elsas, Hans van Eenennaam   +15 more
doaj   +1 more source

CD47/SIRPα axis: bridging innate and adaptive immunity

Journal for ImmunoTherapy of Cancer, 2022
Myeloid immune cells are frequently present in the tumor environment, and although they can positively contribute to tumor control they often negatively impact anticancer immune responses. One way of inhibiting the positive contributions of myeloid cells
Sjoerd H van der Burg, Anneloes van Duijn, Ferenc A Scheeren   +2 more
doaj   +1 more source

Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma

Cells, 2022
The loss of CD47 on aging cells serves as a signal to macrophages to eliminate the target. Therefore, CD47 is a “do-not-eat-me” sign preventing macrophagal phagocytosis via interaction with its ligand SIRPα. Malignant lymphocytes of mycosis fungoides and
Amy Xiao, Oleg E. Akilov
doaj   +1 more source

Myelin down-regulates myelin phagocytosis by microglia and macrophages through interactions between CD47 on myelin and SIRPα (signal regulatory protein-α) on phagocytes

Journal of Neuroinflammation, 2011
Background Traumatic injury to axons produces breakdown of axons and myelin at the site of the lesion and then further distal to this where Wallerian degeneration develops.
Reichert Fanny, Oldenborg Per-Arne, Liraz-Zaltsman Sigal, Gitik Miri, Rotshenker Shlomo   +4 more
doaj   +1 more source

Deletion of SIRPα (signal regulatory protein-α) promotes phagocytic clearance of myelin debris in Wallerian degeneration, axon regeneration, and recovery from nerve injury

Journal of Neuroinflammation, 2019
Background Recovery of function from traumatic nerve injury depends on the ability of severed axons to grow/regenerate back to their target tissues. This is achieved by successfully crossing the lesion site where physical impact severed axons, determined
Gerard Elberg, Sigal Liraz-Zaltsman, Fanny Reichert, Takashi Matozaki, Michael Tal, Shlomo Rotshenker   +5 more
doaj   +1 more source

Research Progress of CD47-SIRPα Signaling Axis as An Innate Immune Checkpoint in Cancer

Zhongliu Fangzhi Yanjiu, 2018
Immune checkpoint inhibitors, including those targeting CTLA-4/B7 and PD-1/PD-L1 inhibitory pathways, are now available for clinical use on cancer patients. Other interesting checkpoint inhibitors are currently under the development.
ZHA Li, YU Jiaojiao, XU Bin
doaj   +1 more source

Advanced Materials for Biologics Delivery to Brain Tumors

Advanced Materials, EarlyView.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng, Yuxue Cao, Maria Kavallaris, Taskeen Janjua, Amirali Popat   +4 more
wiley   +1 more source

Innate Immunocompetent hiPSC‐Derived Neurospheroids Capture Early CNS Responses to rAAV

Advanced Science, EarlyView.
Knowledge of human CNS immune responses to AAV‐based gene therapies remains limited due to the lack of immune‐competent human models. Here, a hiPSC‐derived 3D neuroimmune platform integrating neurospheroids and microglia is established using stirred‐tank bioreactors.
Catarina M. Gomes, Gabriela Silva, Mafalda Aleixo, Marta Gomes, Daniel Simão, Stephan J. Holtkamp, Diana D. Lobo, Pradeep Harish, Rosalind Jenkins, Lekh N. Dahal, Rui J. Nobre, Luís de Pereira de Almeida, Mark Trautwein, Paula M. Alves, Catarina Brito   +14 more
wiley   +1 more source